Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP7317 for Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT03178149Phase 1Recruiting
- Sponsor
- Astellas Institute for Regenerative Medicine
- Start
- Jul 2018
- Primary completion
- Dec 2027
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label trial of ASP7317 in geographic atrophy (GA) and age-related macular degeneration (AMD) (2 arms), sponsored by Astellas Institute for Regenerative Medicine. Primary endpoints: Treatment Emergent Adverse Events at 52 weeks, Serious Adverse Events at 52 weeks and 1 more. Started Jul 2018; status: recruiting.
02
Drugs
ASP7317
03
Conditions
geographic atrophy (GA)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT03178149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03178149.